J Korean Acad Rehabil Med Search


Journal of the Korean Academy of Rehabilitation Medicine 2002;26(2):208-214.
Changes of Bone Mineral Density, Lipid Profiles, and Biochemical Markers after Combination Therapy of Estrogen and Alendronate in Postmenopausal Osteoporosis.
Kim, Ghi Chan , Jeong, Ho Joong , Chung, Suk Mo , Roh, Kyung Hwan
Department of Rehabilitation Medicine, Kosin Medical College, Busan, Korea. jungsm8@hanmail.net
폐경 후 골다공증 환자에서 지속적 호르몬 대체요법과 Alendronate의 병합치료
김기찬, 정호중, 정석모, 노경환
고신대학교 의학부 재활의학교실

To investigate the changes of bone mineral density (BMD), biochemical bone markers, and lipid profiles after combination therapy of continuous hormonal replacement therapy (c-HRT) and alendronate in postmenopausal osteoporosis.

We studied 89 women with postmenopausal osteoporosis (T-score<2.5) who visited at Department of Rehabilitation Medicine, Kosin Medical Center from August 1999 to March 2001. Subjects were divided into two groups; Group I (n=40), treated with estrogen and alendronate (10 mg/day), and Group II (n=49), treated with estrogen alone. BMD at the lumbar spine and femur, osteocalcin, urine deoxypyridinoline and lipid profiles were measured at baseline and 1-year after treatment.

1) BMD at the lumbar spine increased significantly

in two groups, and BMD in Group I increased significantly more than that in Group II. But, change of BMD on femoral neck was not significantly different. 2) Biochemical bone markers (osteocalcin and urine deoxypyridinoline) decreased significantly in two groups. 3) Total cholesterol and LDL cholesterol decreased significantly in two groups, but HDL cholesterol and triglyceride showed no significant change in two groups. There was no significant differences between two groups in lipid profiles.

We concluded that combination therapy with c- HRT and alendronate in postmenopausal osteoporosis was more effective than c-HRT, which would not influence on positive effect of estrogen for lipid metabolism. (J Korean Acad Rehab Med 2002; 26: 208-214)

Key Words: Alendronate, Continuous hormonal replacement therapy (c-HRT), Postmenopausal osteoporosis, Alendronate, Continuous hormonal replacement therapy (c-HRT)


Browse all articles >

Terms of Use   |   Privacy Polity
Editorial Office
Department of Rehabilitation Medicine, Seoul National University Hospital
101 Daehak-ro, Jongno-gu, Seoul, Korea
Tel: +82-10-8678-2671    Fax: +82-2-6072-5244    E-mail: edit@e-arm.org; edit.karm@gmail.com
Business Registration: 110-82-07460                

Copyright © 2024 by Korean Academy of Rehabilitation Medicine.

Developed in M2PI

Close layer